ArticleCureus2025
Alkaptonuria: Clinical Spectrum of a Diagnosed Case in Bahrain With a Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alkaptonuria (AKU) is a rare metabolic condition caused by mutations within a gene coding for homogentisate 1,2 dioxygenase enzyme involved in the tyrosine catabolism pathway. This mutation will result in the accumulation of homogentisic acid (HGA) in the body. AKU is a multi-systemic slowly progressing disease. The onset of its clinical presentation may vary based on the extensive disposition of the HGA. Initially, it might be asymptomatic, and symptoms usually appear in the second or third decades due to the formation of HGA, melanin compounds that accumulate in the cartilage leading to ochronosis. Furthermore, by the fourth or fifth decade, ochronotic arthropathy occurs, along with other extra-articular complications such as cardiovascular manifestations (e.g., valvular heart disease), renal and prostatic stones, and hypothyroidism. Management of this condition is mainly symptomatic, focusing on the treatment of its complications. Recently, the use of nitisinone (NTBC) has shown stabilization of disease manifestations. In this report, we present in detail the first AKU-diagnosed patient, including the clinical presentations, radiological findings, genetic results, and clinical outcomes, from the main tertiary hospital in Bahrain. Moreover, we conducted a thorough literature review on this rare condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.